abstract BACKGROUND AND OBJECTIVES: Treatment of suspected infection is a mainstay of the daily work in the NICU. We hypothesized that NICU antibiotic prescribing practice variation correlates with rates of proven infection, necrotizing enterocolitis (NEC), mortality, inborn admission, and with NICU surgical volume and average length of stay.
Wide variation in hospital resource use with little connection to patient outcomes has been reported for diverse care contexts. 1 These patterns challenge the belief that directing incrementally more resources at certain health care problems necessarily produces incrementally better results. For instance, the Centers for Disease Control and Prevention estimates that as much as 50% of prescribed antibiotics are either unnecessary or suboptimally effective as prescribed. 2 Wide variation in outcomes has also been documented among NICUs. 3, 4 However, relatively little information is available connecting NICU resource use with patient outcomes. Prevention of central line associated bloodstream infection (CLABSI) and other hospital-acquired infection in the NICU has been a recent target of quality improvement efforts. [5] [6] [7] Such efforts share the broader strategic objective of reducing health care misuse (1 of 3 categories of quality problems, along with underuse and overuse). 8 In 2012, more than 60% of NICUs in California reported a CLABSI rate of zero. 9 It is unclear whether reported success of such infection prevention efforts affects the perceived overall burden of NICU infection and consequent use of antibiotics. Antibiotics used in circumstances where patient benefits are not clearly demonstrable would constitute overuse. 10 Eliminating overuse is considered perhaps the most effective way to improve quality and reduce cost, 10 yet the strategy has largely been neglected in quality improvement research and interventions. 11 Antibiotics are commonly used drugs in NICUs. 12 If overuse is occurring in the NICU, the consequences extend beyond unwarranted resource use and increased financial cost of care. Neonatal antibiotic exposure is associated with increased risk of necrotizing enterocolitis (NEC), nosocomial infection (NI), and mortality, [13] [14] [15] as well as with asthma later in life. 16 Additionally, antimicrobial use is associated with the selection of multidrug-resistant pathogens, themselves associated with increased morbidity, mortality, cost, and length of stay. 17 To explore the possibility of overuse of antibiotics for neonates, we measured NICU antibiotic practice variation and examined relationships with proven infection and other factors unambiguously connected with antibiotic exposure.
METHODS
California Children's Services (CCS), within the California Department of Health Care Services, confers state approval for 3 levels of NICU care: regional, community, and intermediate, 18 generally corresponding to American Academy of Pediatrics levels IV, III, and II, respectively. 19 CCS standards include a requirement for annual data reporting of specific variables. Beginning in 2013, CCS required NICUs to report annual antibiotic use rate (AUR). All 116 CCS-approved NICUs submit their data to the California Perinatal Quality Care Collaborative (CPQCC), 4 which prepares an annual report for each NICU and submits an aggregate data set to CCS. Of 136 NICUs in California, 20 132 participate in the CPQCC. Thus, the combined CPQCC/ CCS data set approximates a population-based database describing NICU care and outcomes for most of the 503 738 total live births in California in 2013. 21 The authors conducted the study analysis by using the CPQCC/CCS data set for calendar year 2013. This study was approved by the Stanford University Institutional Review Board.
Study Variable Definitions
AUR is the total number of patientdays that infants were exposed to 1 or more antibacterial or antifungal agents administered intravenously or intramuscularly per 100 patient-days in the reporting NICU, expressed as a percentage. With increasing adoption by hospitals of computerized provider order entry systems, 22 NICUs were encouraged to obtain this information via a specifically designed database query, although not all units had this capability. Early onset sepsis (EOS) rate is the percentage of infants with bacterial or fungal infection diagnosed by blood culture within 2 days of birth. CLABSI rate is the number of laboratory confirmed bloodstream infections where a central line (including an umbilical catheter) was in place for .2 days on the date of the event per 1000 central-line days. 23 Inborn admission rate is the proportion of all live births at a hospital who were admitted to the NICU. Number of surgical cases counts the number of patients undergoing a surgical procedure, excluding circumcision, cannulation/ decannulation for extracorporeal membrane oxygenation, placement/ removal of peritoneal dialysis catheters, chest tube placement, or central line placement. NICU mortality rate is the ratio of all NICU deaths to the total number of NICU admissions.
Certain CCS/CPQCC variables are restricted to infants who were 401 to 1500 g or 22 to 29 weeks' gestation at birth. NI rate is the percentage of infants with bacterial or fungal infection diagnosed by blood culture on or after 3 days after birth; fungal infection rate is the percentage of infants with a fungal infection diagnosed by blood culture on or after 3 days after birth; NEC rate is the percentage of infants diagnosed with NEC; and average length of stay (AvLOS) is the average NICU length of stay in days for patients discharged from the hospital.
Statistical Methods
The unit of observation and unit of analysis was the individual NICU. We stratified the overall analysis by NICU levels of care and lowest/highest AUR quartiles (quartile 1/quartile 4). Sample means were compared by analysis of variance; unequal variances were assessed by Bartlett's test for equal variances. P values reflect 2-tailed distributions. We estimated the magnitude of linear correlation by Pearson's correlation coefficient, unless extreme outlier values or unmet distributional assumptions warranted Spearman's rank correlation. We used Stata 13 24 (Stata Corp, College Station, TX) for all computations and graphical displays.
RESULTS
Among 132 CPQCC NICUs, 5 reported either missing AUR or fewer than 1 of 100 patient-days (values considered clinically implausible), and were dropped from the analysis. The remaining 127 NICUs admitted 52 061 infants and provided care for 746 051 patient-days, of which 214 323 entailed antibiotic exposure.
AUR variation is detailed in Fig 1 In either the overall or stratified analysis, there were no statistically significant correlations between AUR and proven infection, NEC, surgical case volume, or NICU mortality (Table 2 ). Comparing NICUs in the lowest quartile of AUR values with NICUs in the highest quartile revealed no significant difference in burden of proven infection, NEC, surgical case volume, or mortality rate (Table 2) . Figure 2 illustrates no correlation between AUR and NI among NICUs in either the lowest or highest AUR quartile (Spearman's correlation coefficient = 0.12, P = .51; and Pearson's correlation coefficient = 20.02, P = .93, respectively). Table 3 describes the percentage of NICUs reporting specific proven infection rates of zero among providers in the lowest and highest AUR quartiles. The proportion of high quartile AUR NICUs with specific infection rates of zero is noteworthy, especially among intermediate NICUs.
Examining AUR and other NICU resource use revealed no correlation between AUR and AvLOS overall, but they were positively correlated among regional-level NICUs (Fig 2; Pearson's correlation coefficient = 0.78; P , .001). Compared with regional NICUs in the lowest AUR (Table 3) .
Earlier reports of antibiotic use are less comprehensive or specific, but their findings are consistent with our observations. Among 40 children's hospitals, antibiotic-days ranged between 36.8% and 60.1% of patientdays; the variation was unexplained by patient-or hospital-level factors associated with antibiotic treatment. 25 Among 29 NICUs, the point-prevalence of antibiotic use ranged between 15.2% and 85.7% of patients (median = 45.8%). 12 Among 323 acute care hospitals, almost 56% of patients received antibiotics during their hospitalization. 26 Finally, among 19 hospitals that reported antibiotic use to the National Healthcare Safety Network in 2012, critical care units reported a median of 937 days/1000 patient-days; ward locations, a median of 549 days/1000 patientdays; the widest variation between the 10th and 90th percentiles was threefold, among the ward locations. 26 The consistency of our data with these earlier reports also mitigates concern over possible estimation errors in data reported by NICUs unable to obtain antibiotic use values via a specifically designed pharmacy database query; such NICUs instead depend upon manual abstraction of data from each medical record. Additionally to this point, if such potential errors were inaccurate in a systematic way, the effect on data patterns would tend to make it even more unlikely to find the observed absence of correlation detailed in Table 2 .
Our data set accounts for almost all proven microbial infection. Although incidence of NI only reflects infants who were 401 to 1500 g or 22 to 29 weeks' gestation at birth, most NI occurs in this subpopulation. 27 33 These authors estimate that their approach could decrease antibiotic treatment in as many as 240 000 newborns nationwide. 33 In contrast to other reports, [13] [14] [15] we did not find a relationship between AUR and NEC, NI, or mortality. Each of these previous studies analyzed duration of antibiotic exposure in individual patients during particular portions of the NICU hospitalization, such as the first week of life. [13] [14] [15] Because the unit of observation and analysis in our study is the NICU, the previously reported associations could still be operating, but may be obscured by averaging exposure across all patients in an entire NICU and across entire hospital courses for all patients. The NICU-level unit of observation and analysis also precludes adjusting outcomes for differences in baseline characteristics among patients. For example, EOS incidence and case fatality are substantially higher in African American preterm infants compared with non-African American term infants. 28 We mitigated this limitation to some degree by stratifying our analysis by NICU level, with large numbers of patients in each level. Analytical limitations notwithstanding, the available evidence does not support the current range of practice in treating unproven infection.
Case-mix adjustment is useful if study goals include a comparison among NICUs of proven infection and other factors unambiguously connected with antibiotic exposure. However, our primary study objective was to examine how NICU antibiotic practice variation relates with proven infection and other factors unambiguously connected with antibiotic exposure. Whether Although AUR was independent of clinical correlates, it sometimes was correlated with resource use. At regional-level NICUs, higher AUR was correlated with both higher inborn admission rates and higher AvLOS. At intermediate-level NICUs, higher AUR was correlated with higher inborn admission rates. Elucidating the determinants and directionality of these relationships requires additional investigation.
CONCLUSIONS
The 40-fold variation in antibiotic use across California NICUs is unsupported by the burden of proven infection, other factors unambiguously warranting antibiotic exposure, or the peer-reviewed literature. Currently measured rates of proven infection provide an incomplete and possibly misleading depiction of NICU care relating to imputed microbial disease. Therefore, it is reasonable for other organizations that track NICU performance to add AUR to their arrays of evaluative variables. The goal of such benchmarking efforts should be to identify warranted ranges of AUR for NICUs providing different levels of care. 38 Additional study is also needed to elucidate the determinants and directionality of relationships between AUR and other resource use.
